The management of hormone-relapsed prostate cancer

BJU International

Volumn 92, Issue 8, 2003, Pages 860-868

  Clarke, N W ^a,b  

^a HOPE HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; ATRASENTAN; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ERYTHROPOIETIN; ESTRAMUSTINE PHOSPHATE; HORMONE; HYDROCORTISONE; IBANDRONIC ACID; KETOCONAZOLE; MATRIX METALLOPROTEINASE INHIBITOR; MITOXANTRONE; PREDNISOLONE; STEROID; ZOLEDRONIC ACID;

ANOPLASTY; BLADDER DISEASE; BLADDER IRRIGATION; BLADDER NECK STENOSIS; BONE DISEASE; BONE MARROW DEPRESSION; BONE METASTASIS; BONE PAIN; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CATHETERIZATION; COMPRESSION THERAPY; COUNSELING; DISSEMINATED INTRAVASCULAR CLOTTING; FRACTURE FIXATION; HEMATURIA; HUMAN; KIDNEY FAILURE; LYMPHEDEMA; MICTURITION DISORDER; NEPHROSTOMY; ORTHOPEDIC SURGERY; PATHOLOGIC FRACTURE; PATIENT CARE; PATIENT COUNSELING; PERCUTANEOUS NEPHROSTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PSYCHOLOGICAL ASPECT; RECTUM DISEASE; REVIEW; SPINAL CORD COMPRESSION; THROMBOCYTE DYSFUNCTION; TRANSURETHRAL RESECTION; URETER OBSTRUCTION; URETER STENT; URINARY DIVERSION; URINE INCONTINENCE;

ANTINEOPLASTIC AGENTS, HORMONAL; BONE MARROW DISEASES; BONE NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FRACTURES, SPONTANEOUS; HUMANS; INTESTINAL OBSTRUCTION; LYMPHEDEMA; MALE; NEOPLASM RECURRENCE, LOCAL; PAIN; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RECTAL DISEASES; SPINAL CORD COMPRESSION; URETERAL OBSTRUCTION;

EID: 0345257723     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04494.x     Document Type: Review

References (82)

1. Mazur AW, Thompson IM. Efficacy and morbidity of 'channel' TURP. Urology 1991; 38: 562-628
2. Kirby RS, Cristmas TJ, Brawer M. Prostate Cancer. London, Baltimore: Mosby-Wolfe, Times-Mirror International Publishers Ltd, 1995
3. Thorpe AC, Cleary R, Coles J et al. Deaths and complications following prostatectomy in 1400 men in the Northern Region of England. Br J Urol 1994; 74: 559-65
4. Wyatt MG, Stower MJ, Smith PJB, Roberts JBM. Prostatectomy in the over 80 year old. Br J Urol 1989; 64: 417-9
5. Esper P, Redman GR. Supportive care, pain management an quality of life in advanced prostate cancer. Urol Clin N Am 1999; 26: 375-89
6. Pergamen MC, Swain WR, Blackard CE. Disseminated intravascular coagulation in the urological patient. J Urol 1976; 116: 1-6
7. Doyle D. Domiciliary Palliative Care, a Guide for the Primary Care Team. Oxford: Oxford University Press, 1994
8. Dearnaley DP. Radiotherapy of prostate cancer: established results and new developments. Semin Surg Oncol 1995; 11: 50-9
9. Fossa SD. Palliative pelvic radiotherapy in patients with hormone resistant prostate cancer. Prog Clin Biol Res 1987; 243B: 479
10. Paul AB, Love C, Chisholm GD. The management of bilateral ureteric obstruction and renal failure in advanced prostate cancer. Br J Urol 1994; 5: 642-5
11. Villavicencio H. Quality of life of patients with advanced and metastatic prostatic carcinoma. Eur Urol 1993; 24: 118-21
12. Hamdy FC, Williams JL. Use of dexamethasone for ureteric obstruction in advanced prostate cancer: percutaneous nephrostomies can be avoided. Br J Urol 1995; 75: 782-5
13. Megalli MR, Gursel CD, Demirag H et al. External beam radiotherapy in ureteral obstruction secondary to locally invasive prostate cancer. Urology 1975; 3: 562-4
14. Michigan S, Catalona WJ. Ureteral obstruction from prostatic carcinoma, response to endocrine and radiation therapy. J Urol 1977; 118: 733-8
15. Pollak JS, Rosenblatt M, Egglin T et al. Initial experience with ureteral obstructions with the wallstent endoprosthesis. J Vasc Interv Radiol 1995; 6: 417-25
16. Kulkarni R, Bellamy E. Nickel titanium shape memory alloy Memokath OSI ureteral stent for managing long-term ureteral obstruction: 4 year experience. J Urol 2001; 166: 1750-4
17. Jabour ME, Desgrandchamps F, Angelscu E et al. Percutaneous implantation of subcutaneous prosthetic ureters: long term outcome. J Endo Urol 2001; 15: 611-4
18. Gobel BH. Bleeding disorders. In Groenwald S, Frogge M, Goodman M, Yarbro C eds, Cancer Nursing - Principles and Practice. Boston, MA: Jones Bartlett, 1993: 575-607
19. Esper P, Pienta KJ. Supportive care in the patient with hormone refractory prostate cancer. Semin Urol Oncol 1997; 15: 56-64
20. Albers PH, Cappell R, Schwaibold H et al. Erythropoietin in urologic oncology. Eur Urol 2001; 39: 1-8
21. Beshara S, Letochka H, Linde T et al. Anaemia associated with advanced prostatic adenocarcinoma, effects of recombinant human erythropoietin. The Prostate 1997; 31: 153-60
22. Johannsson JE, Wersall P, Brandberg Y et al. Efficacy of Epoeitin beta on haemoglobin, quality of life and transfusion needs in patients with anaemia due to HRPC - a randomised study. Scand J Nephrol 2001; 35: 288-94
23. Tofe AJ, Francis MD, Harvey WJ. Correlation of neoplasms with incidence and localisation of skeletal metastases. An analysis of 1355 diphosphonate bone scans. J Nucl Med 1975; 16: 986-9
24. Carlin B, Andriole GL. The natural history, skeletal complications and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88: 2989-94
25. Clarke NW, McClure J, George NJR. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991; 68: 74-80
26. Spencer H, Lewin I. Derangements of calcium metabolism in patients with neoplastic bone involvement. J Chronic Dis 1963; 16: 713-26
27. Mahadevia P, Ramaswamy A, Greenwald E et al. Hypercalcaemia in prostate cancer. Arch Int Med 1983; 143: 1339-42
28. Soerdjbalie-Maikoev Pelger RE, Lycklama a Nijeholt A, Arndt JW et al. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Imaging 2002; 29: 494-08
29. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Canc 1987; 55: 61-6
30. Neville-Webbe HC, Holden I, Coleman E. The anti-tumour activity of bisphosphonates. Canc Treatment Rev 2002; 28: 305-19
31. Berrutti A, Dogliotti L, Tucci M et al. Metabolic bone disease induced by prostate cancer, rationale for the use of bisphosphonates. J Urol 2001; 166: 2023-31
32. Townsend MF, Sanders WH, Northway RU et al. Bone fractures associated with LHRH agonists used in the treatment of prostate cancer. Cancer 1997; 79: 545-50
33. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005-7
34. Clarke NW, McClure J, George NJR. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol 1992; 69: 64-70
35. Smith JA. Palliation of painful bone metastases from prostate cancer using disodium etidronate: results of a randomised prospective double-blind study. J Urol 1989; 141: 85-7
36. Dearnaley DP, Sydes MR on behalf of the MRC Prostate Collaborators. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer. Proc ASCO 2001; 20: 17A
37. Ernst DS, Tannock IF, Venner PM et al. Randomised placebo controlled trial of mitoxantrone/prednisolone and clodronate versus mitoxantrone/ prednisolone alone in patients with HRPC and pain. NCIC Clinical Trials Group Study. Proc ASCO 2002; 21: 177A
38. Saad F, Gleason DM, Murray R et al. A randomised placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Nat Canc Inst 2002; 94: 1458-68
39. Canil CM, Tannock IF. Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone. J Nat Canc Inst 2002; 94: 1422-3
40. Osborne J, Getzenberg RH, Trump DL et al. Spinal cord compression in prostate cancer. J Neurol Oncol 1995; 23: 135-47
41. Bayley A, Milosevic M, Bland R et al. A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma. Cancer 2001; 92: 303-10
42. Kuban DA, El-Mahid AM, Siegred SV. Characteristics of spinal cord compression in adenocarcinoma of the prostate. Urology 1986; 28: 364-9
43. Huddart RA, Rajan B, Lau M et al. Spinal cord compression in prostate cancer. Treatment outcome and prognostic factors. Radiother Oncol 1997; 44: 229-36
44. Iacovou J, Marks JC, Abrams PH et al. Cord compression and carcinoma prostate: is laminectomy justified. Br J Urol 1985; 57: 733-6
45. Shuttleworth ED, Blandy JP. Carcinoma of the prostate. In Blandy JP ed. Urology. Oxford: Blackwell Scientific Publications, 1976: 926-53
46. Rose MR, Kagan AR. The final report on the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology. Int J Radiat Oncol Biol Phys 1998; 40: 117-24
47. Staniland E, Leir J. The effect of single fraction compound to multiple fractions in painful bone metastases in prostate cancer. Radiother Oncol 1999; 52: 101-9
48. Price P, Hoskin PJ, Easton D et al. Prospective randomised trial of single and multi-fractional radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 1986; 65: 247-55
49. Hosking PJ. Scientific and clinical aspects of radiotherapy in the relief of bone pain. Cancer Surv 1988; 7: 69-86
50. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases. Final results of the radiation therapy oncology group. Cancer 1982; 50: 893-9
51. Zelefsky MJ, Scher H, Forman JD et al. Palliative hemi-skeletal irradiation for widespread metastatic prostate cancer. A comparison of single dose and fractionated regimens. Int J Rad Oncol Biophys 1989; 17: 1281-5
52. Salazar OM, Sandhu T, La Matta NW et al. Fractional half body irradiation (HBI) for the rapid palliation of widespread symptomatic, metastatic bone disease: a randomised phase III trial of the IAEA. Int J Radiat Oncol Biol Phys 2001; 50: 765-75
53. Friedland J. Local and systemic radiation for palliation of metastatic disease. Urol Clin N Am 1999; 76: 391-402
54. 89strontium for patients with bone metastases from prostate cancer. BJU Int 2000; 86: 929-34
55. 89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991; 64: 816-72
56. 89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27: 954-8
57. 89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40
58. Kylama T, Tammela TL, Lincholm TS, Seppanen J. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann Chir Gynaecol 1994; 83: 316-9
59. Cresswell SM, English PJ, Hall RR et al. Pain relief and quality of life assessment following intravenous and oral clodronate in hormone escaped metastatic prostate cancer. Br J Urol 1995; 76: 360-5
60. Purohit OP, Anthony C, Radstone CR et al. High dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1995; 70: 554-8
61. Heidenreich A, Elert A, Hofmann R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prost Con Prost Dis 2002; 2: 231-5
62. Ernst DS, Brasher P, Hagan N et al. A randomised controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manag 1997; 13: 319-26
63. Kylmala T, Taube T, Tammela T et al. Concomitant intravenous and oral clodronate in the relief of bone pain - a double-blind placebo controlled cross-over study in patients with prostate cancer. Br J Cancer 1997; 76: 939-42
64. Lipton A, Glover D, Harvey H et al. Pamidronate in the treatment of bone metastases: results of 2 dose ranging trials in patients with breast or prostate cancer Ann. Oncol 1994; 5 (Suppl. 7): 35-53
65. Brennan MJ. Lymphoedema following the surgical management of breast cancer. J Pain Sympt Manage 1992; 2: 110-6
66. Chen TF, Eardley I, Doyle PT et al. Rectal obstruction secondary to carcinoma of the prostate treated by trans-anal resection of the prostate. Br J Urol 1992; 70: 643-7
67. Tu SM, Millikan RE, Mengistu B et al. Bone targeted therapy for advanced and androgen independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357: 336-40
68. Casciano R, Petrytlak D. Systematic review of chemotherapy efficacy from controlled trials in hormone refractory prostate cancer. Proc Annu Meet Am Soc Clin Oncol 2001; 20: 2428
69. Petrylak DP. Chemotherapy for androgen independent prostate cancer. Semin Urol Oncol 2002; 3: 31-5
70. Heidenreich A, Van Krioblach R, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol 2001; 39: 121-30
71. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced HRPC. Cancer 1993; 71: 1098-109
72. Tannock IF, Osaba D, Stockelev MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer. Clin Oncol 1996; 17: 1756-64
73. Kantoff PW, Halabi SC, Conway M. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer, results of the cancer and leukaemia group B 9182 study. J Clin Oncol 1999; 17: 2506-13
74. Osaba D, Tannock IF, Ernst SD et al. Health related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitxantrone plus prednisone. J Clin Oncol 1999; 17: 1654-163
75. Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Haematol Oncol Clin N Am 2001; 15: 525-45
76. Berry W, Dakhil S, Gregurich M et al. Phase II randomised trial of single agent weekly docetaxel on HR symptomatic metastatic prostate cancer. Sem Oncol: 2001; 28: 8-15
77. Harris KA, Weinberg V, Bok RA et al. Low dose ketoconazole with replacement hydrocortisone in patients with progressive hormone independent prostate cancer. J Urol 2002; 168: 542-5
78. Ahmann FR, Saad FM, Mercier R et al. Interim results of a phase III study of the MMP inhibitor prinomastat in patients having metastatic JRPC. Proc Ann Meet Am Soc Clin Oncol 2001; 30: 692
79. Carducci MA, Nelson JB, Rowling MK et al. Atrasentan: an endothelin receptor antagonist in refractory PC. safety and pharmacokinetics. J Clin Oncol 2002; 15: 2171-80
80. Tiernan E. Palliative care in urological cancer. Uro-Oncology 2000; 1: 7-10
81. Roth AJ, Holland JC. Psychiatric complications in cancer patients. In Braum MC, Carbone PP eds, Current Therapy in Haemotology-Oncology. 5th edn. St. Louis: Mosby Yearbook, 1995: 609-18
82. Litwin MS, Lubeck DP, Stoddard MC et al. Quality of life before death for men with prostate cancer: results from the CAPSURE database. J Urol 2001; 165: 871-5